Eli Lilly just wrote a $6.3 billion check for Centessa Pharmaceuticals, and if you think this is just about sleep… you’re only reading the first chapter. Yes, the headline asset is cleminorexton (formerly ORX750), an orexin receptor 2 agonist that just wrapped Phase 2a across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. But Lilly didn’t pay $6.3 billion for one Phase 2 drug. They paid for a franchise.
Centessa’s pipeline includes three OX2R agonists at different stages. Cleminorexton is the lead, with Phase 2a data that Centessa calls “potential best-in-class” — though they haven’t shown us the actual efficacy numbers yet, which is… interesting timing for an acquisition announcement. Behind it sits ORX142, already in Phase 1 healthy volunteer studies after FDA IND clearance, and ORX489, described as their most potent OX2R agonist, currently in IND-enabling work through a collaboration with Nxera Pharma.
Centessa OX2R agonist pipeline (acquired by Lilly)
Preclinical
Phase 1
Phase 2
Phase 3
NT1, NT2, idiopathic hypersomnia + planned expansion into neurodegenerative & neuropsychiatric
The strategic logic is clear. Lilly is already a neuroscience powerhouse — donanemab in Alzheimer’s put them on the map in neurodegeneration. Now they’re expanding into sleep medicine, and they’re doing it by buying the deepest orexin franchise available. Centessa’s Phase 1 data showed cleminorexton restoring normative wakefulness at the 2.5 mg dose, with linear PK supporting once-daily oral dosing and — critically — no hepatotoxicity or visual disturbances. That safety differentiation matters in a class where liver signals have torpedoed competitors.
Remember, Centessa started life in 2021 as a $250 million Series A experiment — ten subsidiary biotechs under one asset-centric umbrella. Most of those programs got discontinued. The hemophilia program was shelved in late 2024, freeing up roughly $200 million to double down on orexin. That bet just paid off at 25x the original Series A. The Cambridge-based company had $425 million in cash as of early 2025, and was sitting on what Lilly clearly views as a franchise-defining platform.
Lilly’s stated plan: develop the OX2R agonists across sleep-wake disorders, neurodegenerative diseases, and neuropsychiatric conditions. That’s not a sleep company acquisition. That’s a neuroscience pipeline acquisition wearing a sleep mask.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
